FDAsafety guidance66% confidence
Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Novartis; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Immunology · Transplantation
- Sub-indication
- General
Related signal: FDA Accepts Supplement Application for Sandimmune by Novartis